Artiva Biotherapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 23, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
RA Capital Management, L.P. (Boston-based investment firm) filed an amended Schedule 13D regarding beneficial ownership in Artiva Biotherapeutics, Inc. The filing date is July 23, 2026. The specific changes to ownership percentage, share count, or dollar amount are not disclosed in the header/metadata provided; the actual amendment details are in the referenced documents (primary_doc.html/xml) which are not included in this excerpt.
Why this rating
Schedule 13D amendments are routine disclosures for institutional investors; without disclosed ownership changes materially exceeding 5% or control implications, impact is administrative.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.